Therefore, the use of GLP-1 analogs in clinical practice should not be overlooked, especially in those with poor glycemic regulation in combination with obesity, hypertension, or dyslipidemia52. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.